Celsion (CLSN) +3.6% premarket after CEO Michael Tardugno tells Reuters his company has a $1B cancer therapy with its ThermoDox treatment for liver cancer. CLSN, with a market cap of only ~$73M and just 16 employees, aims to place an old cancer drug into a new delivery method and adding heat in a recipe for success that can address a large unmet need in cancer.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs